PRPH - ProPhase Labs Inc Stock Price, Fair Value and News

$0.26-0.16 (-38.10%)
Delayed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

PRPH Price Action

Last 7 days

-51.8%


Last 30 days

-65.8%


Last 90 days

-87.8%


Trailing 12 Months

-94.8%

PRPH Stock Price

PRPH RSI Chart

MayJunJulAugSepOctNovDec202501020304050607080

PRPH Valuation

Market Cap

6.2M

Price/Earnings (Trailing)

-0.22

Price/Sales (Trailing)

0.49

EV/EBITDA

-0.2

Price/Free Cashflow

-0.44

PRPH Price/Sales (Trailing)

202220232024202501234

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

PRPH Fundamentals

PRPH Revenue

Revenue (TTM)

12.8M

Rev. Growth (Yr)

-62.39%

Rev. Growth (Qtr)

27.16%

20102012201420162018202020222024020M40M60M80M100M120M

PRPH Earnings

Earnings (TTM)

-27.8M

Earnings Growth (Yr)

-28.13%

Earnings Growth (Qtr)

-7.05%

20102012201420162018202020222024-20M020M40M

PRPH Profitability

EBT Margin

-298.21%

Return on Equity

-72.8%

Return on Assets

-30.23%

Free Cashflow Yield

-227.67%

PRPH Investor Care

Shares Dilution (1Y)

32.30%

Diluted EPS (TTM)

-1.54

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
20102012201420162018202020222024020M40M60M80M100M120M
Net sales
YearQ1Q2Q3Q4
202428.7M18.0M12.8M0
202394.4M78.5M62.7M44.4M
202287.8M105.2M113.9M122.6M
202127.9M33.4M39.0M79.0M
20209.4M11.4M12.5M14.5M
201912.0M10.5M10.8M9.9M
201812.5M13.8M13.2M13.1M
20174.0M4.8M6.5M9.9M
201615.8M14.6M11.6M4.2M
201521.8M22.2M21.4M20.6M
201423.7M23.5M22.7M22.1M
201323.9M24.0M24.5M25.0M
201220.3M20.5M20.8M22.4M
201115.7M16.3M16.2M17.5M
2010018.0M16.3M14.5M
200900019.8M
Get all data in R, Python etc through our Historical Stock Data APIs
ProPhase Labs, Inc. engages in the development and commercialization of novel drugs, dietary supplements, and compounds in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It provides a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also offers contract manufacturing services, such as consumer product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, it is involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

ProPhase Labs Inc Frequently Asked Questions


What is the ticker symbol for ProPhase Labs Inc? What does PRPH stand for in stocks?

PRPH is the stock ticker symbol of ProPhase Labs Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ProPhase Labs Inc (PRPH)?

As of Fri Jan 31 2025, market cap of ProPhase Labs Inc is 6.21 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PRPH stock?

You can check PRPH's fair value in chart for subscribers.

Is ProPhase Labs Inc a good stock to buy?

The fair value guage provides a quick view whether PRPH is over valued or under valued. Whether ProPhase Labs Inc is cheap or expensive depends on the assumptions which impact ProPhase Labs Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PRPH.

What is ProPhase Labs Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jan 31 2025, PRPH's PE ratio (Price to Earnings) is -0.22 and Price to Sales (PS) ratio is 0.49. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PRPH PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on ProPhase Labs Inc's stock?

In the past 10 years, ProPhase Labs Inc has provided -0.16 (multiply by 100 for percentage) rate of return.